Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (CH:BMY)
:BMY
BMY Stock Chart & Stats
Day’s Range― - ―
52-Week RangeCHF54.24 - CHF54.24
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$84.66B
Enterprise ValueCHF163.94B
Total Cash (Recent Filing)$10.88B
Total Debt (Recent Filing)$51.24B
Price to Earnings (P/E)19.8
Beta0.00
Next Earnings
Jul 31, 2025EPS Estimate
1.39Last Dividend Ex-Date
Apr 04, 2025Dividend Yield4.82%
Share Statistics
EPS (TTM)1.48
Shares Outstanding2,035,080,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.78
Enterprise Value/Ebitda10.13
Forecast
1Y Price Target
$46.12Price Target Upside-14.98% Downside
Rating ConsensusHold
Number of Analyst Covering21
---
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceQ1 revenues and EPS beat expectations, and FY2025 revenue guidance was raised significantly due to revised FX assumptions.
Product DemandUnderlying demand continues to look strong for key growth drivers like Camzyos and Cobenfy.
Revenue GrowthCobenfy scripts are tracking ahead of what is needed to beat consensus estimates for 2Q25, expecting a revenue of $35.4M, which is 31% above consensus.
Bears Say
Clinical Trial ResultsThe failures of two clinical trials—Camzyos in nHCM and Cobenfy in adjunctive schizophrenia—have contributed to the decline in BMY shares.
Long-term Growth ConcernsThe company faces several years of down earnings due to generic pressures, affecting its growth profile.
Regulatory And Market ChallengesBMY shares have pulled back significantly due to recent sector-wide issues including tariffs, FDA challenges, and drug pricing risks.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.05% Insiders
22.04%
Mutual Funds
0.44% Other Institutional Investors
53.21% Public Companies and
Individual Investors
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was CHF54.24 and its highest was CHF54.24 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is $84.66B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Jul 31, 2025 which is in 86 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Apr 24, 2025. The company reported CHF1.484 earnings per share for the quarter, beating the consensus estimate of CHF1.233 by CHF0.251.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Overvalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of CHF2.007 which represents an annual dividend yield of 4.82%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.39.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,035,080,800 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of CHF1.484 in its last earnings report, beating expectations of CHF1.233. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in CH:BMY
---
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$46.12 (-14.98% Downside)
$46.12 (-14.98% Downside)
Blogger Sentiment
Bullish
CH:BMY Sentiment 92%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $412.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.41%
12-Months-Change
Fundamentals
Return on Equity
31.99%
Trailing 12-Months
Asset Growth
-6.67%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
---
BMY Company Deck
---
BMY Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call showed strong financial performance and successful product launches, which were slightly overshadowed by disappointing clinical trial results and challenges related to the regulatory environment and Medicare Part D redesign.Read More>---
BMY Revenue Breakdown
70.61% U.S.
27.33% International
2.06% Other
---
BMY Stock 12 Month Forecast
Average Price Target
CHF46.12
▼(-14.98% Downside)
Technical Analysis
---